Patents by Inventor Sanjivan Gautam

Sanjivan Gautam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY
    Publication number: 20220331360
    Abstract: The invention provides compositions and methods for using adoptive cell therapy (ACT) for treating cancer in a mammal. Cultured T-cells are provided by (a) obtaining an isolated population of T cells, and (b) culturing the isolated T cells ex vivo in the presence of a cytokine and a lactate dehydrogenase inhibitor.
    Type: Application
    Filed: August 6, 2020
    Publication date: October 20, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Warren J. Leonard, Dalton J. Hermans, Luca Gattinoni, Leonard M. Neckers, Sanjivan Gautam
  • T cells modified to overexpress c-Myb
    Patent number: 11098283
    Abstract: Provided is an isolated or purified T cell comprising an antigen-specific receptor, wherein the antigen-specific receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR), wherein the T cell has been modified to express a transcription factor at a level that is higher than the level of the transcription factor expressed by a T cell that has not been modified to express the transcription factor, wherein the transcription factor is V-Myb Avian Myeloblastosis Viral Oncogene Homolog (c-Myb), a functional variant of c-Myb, or a functional fragment of c-Myb. Related populations of cells, pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells are also provided.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 24, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Sanjivan Gautam, Yun Ji, Luca Gattinoni
  • T CELLS MODIFIED TO OVEREXPRESS C-MYB
    Publication number: 20180258394
    Abstract: Provided is an isolated or purified T cell comprising an antigen-specific receptor, wherein the antigen-specific receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR), wherein the T cell has been modified to express a transcription factor at a level that is higher than the level of the transcription factor expressed by a T cell that has not been modified to express the transcription factor, wherein the transcription factor is V-Myb Avian Myeloblastosis Viral Oncogene Homolog (c-Myb), a functional variant of c-Myb, or a functional fragment of c-Myb. Related populations of cells, pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells are also provided.
    Type: Application
    Filed: August 24, 2016
    Publication date: September 13, 2018
    Applicant: The USA, as represented by the Secretary Department of Health and Human Services
    Inventors: Sanjivan Gautam, Yun Ji, Luca Gattinoni